Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis
Аннотация
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and price after biosimilar entry and aflibercept utilization after faricimab entry. A cross‐country survey assessed off‐label bevacizumab use. Results Ranibizumab utilization declined in seven of 11 countries (−1.0% to −29.8%) despite biosimilar entry and associated price reductions. Significant negative trend changes in ranibizumab utilization were observed in France (−0.449; p < 0.001), Germany (−3.935; p = 0.021) and Spain (−8.648; p = 0.002), while Hungary (+33.7; p < 0.001) and the UK (+3.4; p = 0.005) showed increases. Negative trend changes in ranibizumab's weighted average price per TD were observed in four countries ranging from € −0.083 ( p < 0.001) in Germany to € −1.309 ( p < 0.001) in Hungary. Aflibercept utilization increased across all countries during the study period (+23.6% to +243.3%), but subsequent to faricimab entry, downward utilization trends were observed in several countries, indicating a shift in market dynamics potentially due to extended dosing intervals. Survey results revealed substantial heterogeneity in off‐label bevacizumab use, reimbursement status, liability attribution and compounding practises, underscoring fragmented policy environments that influence treatment access. Conclusion The study found substantial cross‐country variation in anti‐VEGF utilization in Europe. Coordinated policy action is needed to support a sustainable biosimilar uptake in this evolving market.